Pneumococcal disease in the Arabian Gulf: Recognizing the challenge and moving toward a solution

Journal of Infection and Public Health

Volumn 6, Issue 6, 2013, Pages 401-409

  Feldman, Charles ^a   Abdulkarim, Emad ^b   Alattar, Fatma ^c   Al Lawati, Faryal ^d   Al Khatib, Hisham ^c   Al Maslamani, Muna ^e   Al Obaidani, Idris ^f   Al Salah, Mosaab ^g   Farghaly, Mohamed ^c   Husain, Entesar H ^h   Mokadas, Eiman ^h  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Ministry of Health United Arab Emirates   (United Arab Emirates)

^c DUBAI HEALTH AUTHORITY   (United Arab Emirates)

^d ROYAL HOSPITAL   (Oman)

^e HAMAD MEDICAL CORPORATION   (Qatar)

^f MINISTRY OF HEALTH   (Oman)

^g MINISTRY OF HEALTH   (Kuwait)

^h KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Community acquired pneumonia (CAP); Elderly adults; Hajj pilgrims; Invasive pneumococcal disease (IPD); Pneumococcal vaccines; Type 2 diabetes; Vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE; PPSV 23; UNCLASSIFIED DRUG;

AGING; ARAB; AWARENESS; BONE MARROW TRANSPLANTATION; DIABETES MELLITUS; DISEASE SURVEILLANCE; HEALTH CARE PLANNING; HEMATOLOGIC MALIGNANCY; HUMAN; ORGAN TRANSPLANTATION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SMOKING; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

COMMUNITY-ACQUIRED PNEUMONIA (CAP); ELDERLY ADULTS; HAJJ PILGRIMS; INVASIVE PNEUMOCOCCAL DISEASE (IPD); PNEUMOCOCCAL VACCINES; TYPE 2 DIABETES; VACCINATION;

ARAB WORLD; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; MIDDLE EAST; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 84887244527     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2013.06.004     Document Type: Review

References (65)

1. United Nations Department of Economic and Social Affairs Population Division World Population Ageing 1950-2050 2002, Available at: http://www.un.org/esa/population/publications/worldageing19502050/countriesorareas.htm [accessed October 2012].
2. Mirkin B. Arab Human Development Report - Population Levels, Trends and Policies in the Arab Region: Challenges and Opportunities 2012, United Nations Development Series, Available at: http://www.arab-hdr.org/publications/other/ahdrps/paper01-en.pdf [accessed October 2012].
3. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR 2010, 59:1102-1106.
4. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR 2012, 61(40):816-819.
5. World Health Organization Pneumococcal vaccines - WHO position paper. Weekly Epidemiol Rec 2012, 87(14):129-144.
6. World Health Organization Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 2012, 30(32):4717-4718.
7. World Health Organization The global burden of disease report 2004 update.
8. FauciAS, Morens D.M. The Perpetual Challenge of Infectious Diseases. N Engl J Med 2012, 366(5):454-461.
9. Fedson D.S., Musher D.M., Eskola J. Pneumococcal vaccine. Vaccines 1998, 3rd ed.:553-607. WB Saunders, Philadelphia.
10. Mufson M.A. Pneumococcal Pneumonia. Curr Infect Dis Rep 1999, 1(1):57-64.
11. Inverarity D., Lamb K., Diggle M., Robertson C., Greenhalgh D., Mitchell T.J., et al. Death or survival from invasive pneumococcal disease in Scotland: associations with serogroups and multilocus sequence types. J Med Microbiol 2011, 60:793-802.
12. Rueda A.M., Serpa J.A., Matloobi M., Mushtaq M., Musher D.M. The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century. Medicine (Baltimore) 2010, 89:331-336.
13. Harboe Z.B., Benfield T.L., Valentiner-Branth P., Hjuler T., Lambertsen L., Kaltoft M., et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010, 50:329-337.
14. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012, 67(1):71-79.
15. Koksal I., Ozlu T., Bayraktar O., Yilmaz G., Bulbul Y., Oztuna F. Etiological agents of community-acquired pneumonia in adult patients in Turkey; a multicentric, cross-sectional study. TuberkToraks 2010, 58(2):119-127.
16. Weycker D., Strutton D., Edelsberg J., Sato R., Jackson L.A. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010, 28:4955-4960.
17. Janoff E.N., Breiman R.F., Daley C.L., Hopewell P.C. Pneumococcal disease during HIV infection: epidemiologic, clinical, and immunologic perspective. Ann Intern Med 1992, 117:314-324.
18. Klugman K.P., Madhi S.A., Feldman C. HIV and pneumococcal disease. Curr Opin Infect Dis 2007, 20:11-15.
19. Weiskopf D., Weinberger B., Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009, 22(11):1041-1050.
20. Weinberger B., Herndler-Brandstetter D., Schwanninger A., Weiskopf D., Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 2008, 46(7):1078-1084.
21. Caruso C., Buffa S., Candore G., Colonna-Romano G., Dunn-Walters D., Kipling D., et al. Mechanisms of immunosenescence. Immun Aging 2009, 6:10.
22. Ortqvist A., Hedlund J., Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005, 26(6):563-574.
23. Herrero F.S., Olivas J.B. Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med 2012, 33:220-231.
24. Lu R.J., Nuorti J.P. Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009. Am J Epidemiol 2012, 175:827-837.
25. Siemieniuk R.A.C., Gregson D.B., Gill M.J. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis 2011, 11:314.
26. Memish Z.A., Arabi Y.M., Ahmed Q.A., Shibl A.M., Niederman M.S., GCC CAP Working Group Management and prevention strategies for community-acquired pneumonia in the Gulf Corporation Council. J Chemother 2007, Suppl. 1:33-46.
27. World Health Organization Pneumococcal vaccines WHO position paper. WER 2012, 14(87):129-144. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.
28. Kurashi N.Y., al-Hamdan A., Ibrahim E.M., al-Idrissi H.Y., al-Bayari T.H. Community acquired acute bacterial and atypical pneumonia in Saudi Arabia. Thorax 1992, 47(2):115-118.
29. Alhyas L., McKay A., Balasanthiran A., Majeed A. Quality of type 2 diabetes management in the states of the co-operative council for the Arab States of the Gulf: a systemic review. PLoS ONE 2011, 6:e22186.
30. Al-Muhairi S., Zoubeidi T., Ellis M., Nicholls M.G., Safa W., Joseph J. Demographics and microbiological profile of pneumonia in United Arab Emirates. Monaldi Arch Chest Dis 2006, 65(1):13-18.
31. Al-Yaqoubi M., Elhag K. Serotype prevalence and penicillin-susceptibility of Streptococcus pneumoniae in Oman. Oman Med J 2011, 26:43-47.
32. Gautret P., Bauge M., Simon F., Benkouiten S., Parola P., Brouqui P. Pneumococcal vaccination and Hajj. Int J Infect Dis 2011, 15:e730.
33. Al-Ghamdi S.M., Akbar H.O., Qari Y.A., Fathaldin O.A., Al-Rashed R.S. Pattern of admission to hospitals during Muslim pilgrimage (Hajj). Saudi Med J 2003, 24:1073-1076.
34. Madani T.A., Ghabrah T.M., Al-Hedaithy M.A., Alhazmi M.A., Alazraqi T.A., Albarrak A.M. Causes of hospitalization of pilgrims in the Hajj season of the Islamic year 1423 (2003). Ann Saudi Med 2006, 26:346-351.
35. Baharoon S., Al-Jahdali H., Al Hashmi J., Memish Z.A., Ahmed Q.A. Severe sepsis and septic shock at the Hajj: etiologies and outcomes. Travel Med Infect Dis 2009, 7:247-252.
36. Dubai Annual Health Statistical Report Dubai Health Authority 2011, Health Data and Information Analysis Department.
37. Centers for Disease Control and Prevention Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46:1-24.
38. Chowdhury P., Balluz L., Town M., Chowdhury F.M., Bartolis W., Garvin W., et al. Centers for Disease Control and Prevention (CDC). Surveillance of certain health behaviors and conditions among states and selected local areas-behavioral risk factor surveillance system, United States, 2007. MMWR Surveill Summ 2010, 59:1-220.
39. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Active bacterial core surveillance/emerging infections program network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
40. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, 1:CD000422.
41. JCVI JCVI statement on the routine pneumococcal vaccination programme for adults aged 65 years and older 20 July 2011, Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_128704.pdf [accessed October 2012].
42. Jackson L.A., Gurtman A., van Cleeff M., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccinecompared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013, [Epub ahead of print].
43. Jackson L.A., Gurtman A., Rice K., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine inadults 70 years of age and older previously vaccinated with 23-valentpneumococcal polysaccharide vaccine. Vaccine 2013, [Epub ahead of print].
44. Jackson L.A., Gurtman A., van Cleeff M., et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013, [Epub ahead of print].
45. Jackson L.A., Gurtman A., van Cleeff M., et al. 13-Valent Pneumococcal conjugate vaccine (PCV13) enhances the response to subsequent PCV13 and 23-valent pneumococcal polysaccharide (PPSV23) vaccinations in adults 50 years and older [abstract LB-3] 2011, Programs and abstracts of the 49th Annual Meeting of the Infectious Diseases Society of America, Boston, MA, October 20-23.
46. Jackson L.A., Gurtman A., van Cleeff M., et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in pneumococcal vaccine naïve adults, 50-64 years of age [abstract O426]. Clin Microbiol Infect 2011, 17(Suppl. S4):S85.
47. Pollard A.J., Perrett K.P., Beverley P.C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009, 9:213-220.
48. Clutterbuck E.A., Lazarus R., Yu L.-M., Bowman J., Bateman E.A.L., Diggle L., et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012, 205(9):1408-1416.
49. Masur H., Kaplan J.E., Holmes K.K. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America; U.S. Public Health Service; Infectious Diseases Society of America. Ann Intern Med 2002, 137:435-478.
50. Qatar Supreme Council Recommendation on Adult Pneumococcal Vaccines 2012, http://www.sch.gov.qa/ [accessed October 2012].
51. Mokaddas E.M., Rotimi V.O., Albert M.J. Implications for Streptococcus pneumonia penicillin resistance and serotype distribution in Kuwait for disease treatment and prevention. Clin Vaccin Immunol 2008, 15:203-207.
52. Kuwait Ministry of Health Healthcare workers - Adult and Elder 2012.
53. CDC HAJJ. [accessed June 2013]. http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-4-select-destinations/hajj-pilgrimage-saudi-arabia.
54. Ahmed Q.A., Arabi Y.M., Memish Z.A. Health risks at the Hajj. Lancet 2006, 367:1008-1015.
55. Al-Tawfiq J.A., Memish Z.A. The Hajj: updated health hazards and current recommendations for 2012. Euro Surveill 2012, 17(41):20295.
56. Memish Z.A., Rabeeah A.A. Health conditions for travellers to Saudi Arabia for the Umraand Hajj pilgrimage to Mecca: requirements for 2012 (1433). J Infect Public Health 2012, 5(2):113-115.
57. WHO Health conditions for travellers to Saudi Arabia for the pilgrimage to Mecca (Hajj). Weekly Epidemiol Rec 2012, 87(30):277-280.
58. Blank P.R., Schwenkglenks M., Szucs T.D. Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasons. Infection 2009, 37(5):390-400.
59. Blank P., Schwenkglenks M., Szucs T.D. The impact of European vaccination policies on seasonal influenza vaccination coverage rates in the elderly. Hum Vaccin Immunother 2012, 18(3). [Epub ahead of print].
60. Lewin S., Hill S., Abdullahi L.H., de Castro Freire S.B., Bosch-Capblanch X., Glenton C., et al. 'Communicate to vaccinate' (COMMVAC). Building evidence for improving communication about childhood vaccinations in low- and middle-income countries: Protocol for a programme of research. Implement Sci 2011, 6:125.
61. Madar R., Strakova J., Baska T., Kavcova E., Straka S. Pneumococcal vaccination-current situation and perspectives. Bratisl Lek Listy 2005, 106(3):119-122.
62. Al-Muhairi S., Zoubeidi T., Ellis M., Safa W., Joseph J. Risk factors predicting outcome in patients with pneumonia in Al-Ain, United Arab Emirates. Saudi J Med 2006, 27(7):1044-1048.
63. WHO monitoring report. [accessed September 2012]. http://apps.who.int/immunization_monitoring/en/.
64. Bahrain Ministry of Health. Recommended Immunization Schedule for the Expanded Program on Immunization, Bahrain. [accessed June 2013]. http://www.moh.gov.bh/EN/HealthInformation/immunizations.aspx%3Fprint=true.
65. Abu Dhabi Health Authority. Hajj Vaccination Program in Abu Dhabi. [accessed June 2013]. http://www.haad.ae/HAAD/tabid/1198/Default.aspx.